Stocktoria
PLIANT THERAPEUTICS, INC. PLRX
PLIANT THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M | $41.8M | $57.1M |
| R&D expense | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M | $66.2M | $47.4M |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M | -$41.6M | -$1.2M |
| Interest expense | — | — | $1.3M | $791,000 | $0 | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.3M | -$41.5M | -$631,000 |
| EPS (diluted) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.95 | $-4.22 |
| Operating cash flow | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M | -$37.3M | -$2.8M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M | -$38.8M | -$3.7M |
| Cash & equivalents | $45.4M | $71.2M | $63.2M | $33.7M | $51.7M | $50.9M | $85.8M |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M | $295.5M | $119.1M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M | $12.5M | $9.1M |
| Shareholders' equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M | $283.1M | -$76.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | -83.7% | +27.9% | -81.9% | -26.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.